A randomised controlled unblinded multicentre non-inferiority trial with activated vitamin D and prednisolone treatment in patients with minimal change nephropathy (ADAPTinMCN)

Abstract

Background Minimal change nephropathy (MCN) is a common cause of nephrotic syndrome in both adults and children. International guidelines recommend treatment with prednisolone 1 mg/kg/day to adults. This dose is derived from an empirically established dose in children, although children generally attain remission faster and relapse more rapidly than adults. Prednisolone is associated with multiple and serious adverse events. Activated vitamin D has been shown to reduce albuminuria in other glomerular renal diseases with a minimum of adverse events. This study tests the hypothesis that a new treatment regimen in MCN combining reduced dose prednisolone and active vitamin D is as efficient in inducing remission and has fewer and less severe adverse events than standard prednisolone. Furthermore, we aim to establish models allowing for more personalized medicine based on assessment of the individual’s prednisolone metabolism. Methods A randomised controlled multicentre non-inferior unblinded trial including 96 adult, incident patients with biopsy-proven MCN, albuminuria > 3 g/day, and an estimated glomerular filtration rate (eGFR) > 30 ml/min from renal departments in Denmark. Patients are randomised to standard prednisolone (1 mg/kg/day) or reduced prednisolone (0.5 mg/kg/day) and alfacalcidol (0.5 μg/day). The primary outcome is the rate of remissions after 16 weeks and the time from diagnosis to remission. The study will include a saliva test to characterise prednisolone pharmacokinetics and compare them to genetic variations in specific liver enzymes responsible for prednisolone metabolism. Discussion Reducing the prednisolone dose is expected to reduce the number of severe adverse events. This study will examine if reduced prednisolone dose with active vitamin D but without additional immunosuppression is feasible in the treatment of MCN and will reduce the number of adverse events. The findings can potentially change current guidelines for treatment of MCN in adults. Additional outcomes on inter-individual pharmacokinetic and metabolic variations may allow for a more personalised treatment strategy. Trial registration EudraCT 2017-001206-16, ClinicalTrials.gov NCT03210688. Registered on June 3, 2017.

A modern view on the clinical value of the study of oral fluid in the practice of a pediatrician

“…Хотелось бы отметить проведение многоцентрового рандомизированного контролируемого слепого исследования, которое включало салива-тест 96 взрослых пациентов с подтвержденной биопсией болезнью минимальных изменений (БМИ) в больнице Дании [40]. Наряду с проведением саливадиагностики охарактеризована фармакокинетика преднизолона в сравнительном аспекте с генетическими вариациями конкретных ферментов печени, ответственных за метаболизм преднизолона.…”

“…Наряду с проведением саливадиагностики охарактеризована фармакокинетика преднизолона в сравнительном аспекте с генетическими вариациями конкретных ферментов печени, ответственных за метаболизм преднизолона. Полученные данные потенциально могут повлиять на текущие рекомендации по лечению БМИ у взрослых пациентов [40].…”